List view / Grid view
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
3 February 2016 | By Victoria White
The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer...
19 January 2016 | By Snehal Chougule, Allied Market Research
Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration...
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
8 December 2015 | By Victoria White
Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer...
26 October 2015 | By Victoria White
APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer...
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
6 August 2015 | By Victoria White
NICE has opened a second consultation on preliminary draft guidance on olaparib for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
